MEDP at a glance
Medpace Holdings Inc (MEDP, SEC CIK 1668397) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on July 22, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28.
- As of June 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Medpace Holdings Inc (MEDP) shares worth $6.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Troendle August J. on September 30, 2026 of 21,966 shares at $625.47 per share.
- In the last 90 days, MEDP insiders reported 0 open-market purchases ($0) and 31 open-market sales ($208.5M) on Form 4, a net sale of $208.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.5B
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 31 sells
- Net −$208.5M
- 13F holders
- 38 funds
- $6.6B · −2 vs prior quarter
- Latest 8-K
- Jul 22, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Full-service Phase I-IV CRO, serving biotech, pharmaceutical and medical device companies across major therapeutic areas
- ClinTrak-enabled clinical trial management, integrating real-time study metrics with operating procedures
- Expanded laboratory platform: four Central Laboratory locations across the U.S., Belgium, China and Singapore
- Strategic positioning toward small and mid-sized biopharma, emphasizing disciplined execution, therapeutic expertise and timely delivery
- Customer risk-sharing arrangements, including strategic investments, flexible payment terms and fee financing capabilities
Management Discussion & Analysis
- Revenue $2.530B, up 20.0% YoY, driven by Metabolic, Oncology and Central Nervous System activity
- Operating margin 21.1% vs 21.2%, net income $451.1M vs $404.4M
- Best performing areas: Metabolic, Oncology and Central Nervous System, supporting revenue growth
- Operating cash flow $713.2M, capex 1.24% of revenue, share repurchases $912.9M, no indebtedness
- Outlook: organic growth and selective bolt-on acquisitions, with liquidity sufficient for 12 months, but future cash flow and borrowing availability uncertain
Risk Factors
- Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue
- Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital
- Fixed-fee contract overruns: majority of Phase I-IV contracts expose Medpace to underpricing and unrecovered costs
- Operational dependency: ClinTrak and third-party laboratories, logistics providers, drug depots and contract personnel support service delivery
- AI disruption: inadequate generative-AI controls could cause delays or errors in customer offerings
AI summary of the MEDP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $707.3M, up 17.2% YoY from $603.3M, driven by Metabolic, Oncology, CNS and AVAI
- Operating margin 20.8% vs 20.9% YoY, net income $121.4M vs $90.3M
- Net new awards $795.7M, up from $620.5M; backlog $3,014.2M, up 4.9% YoY
- Cash $502.7M vs $497.0M at December 31, 2025; six-month operating cash flow $313.8M
- Capital spending 2.17% of revenue, up 78 basis points; liquidity expected sufficient over next 12 months and longer term
Risk Factors
- No significant changes to previously disclosed risk factors in the fiscal 2025 Form 10-K
- Share repurchase activity: $294.7 million returned to shareholders during fiscal 2026 second quarter
- Liquidity allocation: $526,985,940 remained available under the repurchase plan as of May 31, 2026
AI summary of the MEDP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Medpace reported results for Q2 and six months ended June 30, 2026
- Press release issued July 22, 2026 and furnished as Exhibit 99.1
AI summaries of MEDP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MEDP
Don't miss the next MEDP filing
- Alerts as it files. A push when MEDP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MEDP, by share count.
- Ask anything. An AI agent that reads every MEDP filing and answers with sources.
MEDP alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Troendle August J. | Sell | Sep 30, 2026 | 21,966 | $625.47 |
| Carley Brian T | M | Sep 30, 2026 | 36 | - |
| McCarthy Cornelius P. III | M | Sep 30, 2026 | 28 | - |
| Carley Brian T | M | Sep 30, 2026 | 36 | - |
| Kraft Robert O. | M | Sep 30, 2026 | 32 | - |
| Kraft Robert O. | M | Sep 30, 2026 | 32 | - |
| McCarthy Cornelius P. III | M | Sep 30, 2026 | 28 | - |
| Troendle August J. | Sell | Sep 29, 2026 | 26,701 | $621.02 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.1B | $2.5B |
| Operating Income | - | $446.9M | $534.9M |
| Net Income | $282.8M | $404.4M | $451.1M |
| Op. Margin | - | 21.2% | 21.1% |
| Net Margin | - | 19.2% | 17.8% |
| Balance Sheet | |||
| Total Assets | $1.7B | $2.1B | $2.0B |
| Equity | - | $825.5M | $459.1M |
| ROE | - | 49.0% | 98.3% |
| Per Share | |||
| EPS | $8.88 | $12.63 | $15.28 |
| Cash Flow | |||
| Operating CF | - | $608.8M | $713.2M |
| CapEx | $36.6M | $36.5M | $31.4M |
Source: XBRL data in Medpace Holdings Inc (MEDP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MEDP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 38 | $6.64B |
| Q1 2026 | 40 | $5.29B |
| Q4 2025 | 36 | $6.19B |
| Q3 2025 | 37 | $5.68B |
| Q2 2025 | 33 | $3.47B |
| Q1 2025 | 29 | $2.68B |
| Q4 2024 | 25 | $2.53B |
| Q3 2024 | 23 | $1.33B |
- T. Rowe Price Group+1.78M (+615%)
- Goldman Sachs Group+82.3K (+49%)
- Ameriprise Financial+67.6K (+66%)
- JPMorgan Chase & Co+61.3K (+40%)
- Dimensional Fund Advisors+49.0K (+14%)
- D.E. Shaw & Co−198.1K (-46%)
- Two Sigma Investments−166.8K (-94%)
- FMR LLC (Fidelity)−106.4K (-66%)
- Renaissance Technologies LLC−89.1K (-18%)
- AQR Capital Management−74.9K (-6%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 261 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MEDP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 10-Q | Jul 23, 2026 | Jun 30, 2026 | Analysis |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- CRL · Charles River LaboratoriesServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
MEDP SEC filings: frequently asked questions
Are MEDP insiders buying or selling?
In the last 90 days, Medpace Holdings Inc (MEDP) officers, directors and 10% owners reported no open-market purchases and 31 open-market sales worth $208.5 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MEDP stock?
As of June 30, 2026, the largest Medpace Holdings Inc (MEDP) holders among the 13F filers tracked by SignalX were BlackRock ($1.3 billion), T. Rowe Price Group ($1.1 billion), AQR Capital Management ($677.3 million), Vanguard Portfolio Management LLC ($600.2 million), Vanguard Capital Management LLC ($543.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MEDP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28. The figures come from the XBRL data in the 10-K.
What are the main risks in MEDP's latest 10-K?
In the 10-K filed February 10, 2026, Medpace Holdings Inc (MEDP) flagged: Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue. Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital. (AI summary of the Risk Factors section.)
What did MEDP report in its latest 8-K?
Medpace Holdings Inc (MEDP) filed an 8-K on July 22, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Medpace reported results for Q2 and six months ended June 30, 2026.
What are the latest MEDP SEC filings?
Medpace Holdings Inc (MEDP) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on July 22, 2026 and a Form 4 insider filing on October 2, 2026.
What is MEDP's SEC CIK number?
Medpace Holdings Inc (MEDP)'s SEC Central Index Key (CIK) is 1668397. EDGAR lists every MEDP filing under that number.
Ask anything about MEDP
The research agent reads MEDP's filings, financials, insider trades and 13F holders, then answers with sources.